WR Grace is to acquire Synthetech for $19.2 million, less Synthetech’s unpaid debt and transaction costs at closing, and subject to a minimum cash balance of $600,000. The acquisition will expand Grace's pharmaceutical offering by adding expertise in chiral and peptide intermediate synthesis in addition to capacity for the manufacture of specialty single-site and polypropylene catalysts used to produce plastics.
Baltimore Sun
Wednesday, 15 September 2010
Grace to acquire Synthetech
Monday, 13 September 2010
Thursday, 9 September 2010
Lonza signs manufacturing deal with GSK
GlaxoSmithKline has selected Lonza to produce early stage monoclonal antibodies from its biopharmaceutical pipeline. Initially Lonza will manufacture clinical trial batches of five compounds currently in Phase I and II. In addition GSK will also have flexible access to Lonza's capabilities for future demand dependent upon progression of molecules through late stage development and commercial launch.
Reuters
Socma welcomes R&D Tax Credit decision
Socma has welcomed the decision by US President Barack Obama to to expand and simplify the R&E Tax Credit and to make it permanent to help encourage future productivity and growth. Socma has advocated for this for a numb roof years, said Socma President and CEO Lawrence Sloan welcoming the plan.
Socma
Tuesday, 7 September 2010
Tuesday, 31 August 2010
Jubilant signs $33m CRAMS deal
Jubilant Organosys has signed its second major CRAMS deal in a week. The company has signed a $33m, long-term contract with a US life sciences company. R Sankaraiah, Jubilant's Executive Director of Finance, said the company would book $250m orders in this year and $250m-$300m in the next three-four years.
Money Control
Lonza acquires Vivante
Lonza has purchased Vivante GMP Solutions to give it a foothold in the viral-based manufacturing market. Lonza said the acquisition advances its strategy to broaden its biologics custom service offering for the growing viral vaccine and gene therapy markets. Vivante, which is based in Houston, TX, produces GMP viral-based therapeutics.
Lonza
CMC adds disposable manufacturing
CMC Biologics has completed the addition of a state-of-the-art biopharmaceutical disposable manufacturing facility at its Seattle, WA site. CMC Biologics has partnered with Hyclone to supply the multi-purpose, single-use facility with processing equipment, including a 100L and two 500L single-use bioreactors and disposable mixers.
Genetic Engineering and Biotechnology News
Tuesday, 24 August 2010
Jubilant signs CRAMS deal
Jubilant Organosys has signed a $51m, four-year research and manufacturing deal with an unnamed US company. The company is in discussions to expand the contract, which could be extended by a further five years. R Sankaraiah, Jubilant's Executive Director of Finance, said the deal takes Jubilant;s CRAMS order book over $1bn.
Money Control
Thursday, 19 August 2010
Wednesday, 18 August 2010
Aesica invests in high containment
Aesica is investing £3m in a new high containment facility at its Queensborough, UK, site. The facility, which is due to be completed by May 2011, will enable Aesica to manufacture potent drugs typically classed as Safebridge category 3 and significantly extend its current capabilities in the formulation and packaging of liquid and solid dosage forms. In addition, the new facility will also include security measures that will ensure it can manufacture Schedule II controlled drugs such as opiates.
The Northern Echo
Tuesday, 17 August 2010
EMA and FDA plan joint inspections
The European Medicines Agency (EMA) and the US FDA are seeking potential candidate companies for a joint GMP inspection pilot programme for manufacturers of medicinal products. The agencies are hoping to see whether greater international collaboration can help to distribute inspection capacity allowing more manufacturing sites to be monitored and reducing unnecessary duplication.
EMA
Monday, 16 August 2010
Carbogen hinders Dishman
Dishman's Q1 turnover fell 12% to $43.2m. The company's CFO, VVS Murthy, put the fall down to reduced revenues at its Carbogen subsidiary. However, he expects Carbogen to see an overall 10% rise in sales over the full year.
Money Control
Thursday, 5 August 2010
Senator introduces safe drug manufacturing bill
US Senator, Michael Bennet, has introduced a bill, the US Drug Safety and Accountability Act of 2010, which aims to strengthen manufacturing quality standards, enhance the US FDA’s ability to track foreign manufacturing sites, and increase the authority of FDA to make drug product recalls. Socma welcomed the introduction of the bill and thanked the Senator for "introducing this common sense legislation which will strengthen the FDA and increase public health and safety by providing additional quality controls on drugs and their ingredients."
Senator Bennet
Socma
US consumers don't trust safety of foreign manufactured drugs
A survey conducted by the Pew Prescription Project has shown that US consumers do not trust the safety and freedom from contamination of drugs manufactured overseas. 78% of those polled trusted US made drugs, but only 6% trusted those made in China, 8% India and 30% Ireland. Swiss manufactured products were trusted by 47% and Canada made 60%.
Pharma Times
Ampac revenues rise in Q3
Ampac's fine chemicals businesses reported revenues of $20m in its Q3 ended June, compared to $15.6m in 2009, reflecting an increase in revenues from products in development. However, the operating loss for the quarter grew from $0.8m to $2.5m as a result of higher than anticipated costs associated with validating a process change for a core product and general manufacturing inefficiencies.
Ampac
Wednesday, 4 August 2010
AMRI revenues rise in Q2
Q2 revenues for AMRI's contract division rose 5% to $40.7m. The small scale manufacturing business revenues rose 1% to $8.2m and the large scale manufacturing revenues rose 10% to $21m.
AMRI
Pfenex awarded anthrax tech contract
The US Department of Health and Human Services has awarded Pfenex $18.8m contract to support the development of a robust Pfenex Expression Technology based production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax. Pursuant to the contract, Pfenex will identify high producing expression strains capable of producing high titers of stable rPA and then develop commercial cGMP manufacturing process.
Xconomy
Cambrex sales fall
Q2 sales at Cambrex fell 4% to $57.4 million. Cambrex said the decrease is primarily due to lower demand for certain larger products including the effects of a supply chain disruption at a customer's facility, lower pricing on generic APIs and a renegotiated contract extension for certain drug delivery products resulting in lower pricing. However the company saw higher sales volume of controlled substances and generic APIs.
Outsourcing Pharma
Tuesday, 3 August 2010
DSM Pharma sales rise
DSM's Pharmaceutical Products business unit reported 5% sales growth in Q2 2010 compared to 2009. However, profit fell as a result of a challenging business environment and unfavourable product mix. DSM said the drop in results was somewhat compensated by the development of the US dollar.
DSM
Aesica raises £20m
Lloyds TSB Corporate Markets has provided £20m to Aesica Pharmaceuticals to support its continuing expansion through organic growth and acquisitions.
Pharmacy Business
Monday, 2 August 2010
SynCo to manufacture second product for Versartis
SynCo Bio Partners has extended its collaboration with Versartis, Inc. SynCo will scale-up a second manufacturing process on behalf of Versartis and provide fill and finish services for the manufacture, testing and release of formulated Drug Product vials.
Pharmaceutical Business Review
Aptuit partners with Siena
Siena Biotech has acquired a minority stake in Aptuit’s operations in Verona, Italy. In return, Aptuit will become the provider of choice for Siena’s development pipeline of compounds, focused in three key therapeutic areas, including Alzheimer’s disease, Huntington’s disease and oncology.
Mass High Tech
Fine chems sales rise at Albemarle
Sales for Albemarle's Fine Chemistry business rose 36% to $141.2m in Q2. The company said this was the result of increased volumes in both our performance chemicals and fine chemistry services businesses, and partly offset by product mix.
Business Week
Wednesday, 28 July 2010
Signs of recovery for SAFC
Sales for Sigma-Aldrich's SAFC business unit showed double-digit growth in Q2, rising to $157m. The company said that several of the SAFC markets that were depressed in 2009 are beginning to show good signs of recovery. Jai Nagarkatti, Sigma-Aldich Chairman, President and Chief Executive Officer, said "I think SAFC pharma business still is not recovered to the extent that we would like to see it recover" and Rakesh Sachdev, Senior Vice President and Chief Financial Officer, added that "we expect the SAFC pharma business to improve in the second half".
Seeking Alpha
Thursday, 22 July 2010
Custom manufacturing sales hit Lonza
Profits for H1 2010 at Lonza were CHF135m up 14% from CHF118m in 2009, however sales fell 2% to CHF1301m. In the custom manufacturing division sales fell almost 7% to CHF658m due to anticipated low capacity utilisation in Portsmouth and Hopkinton in Q1 2010. In the chemical manufacturing business Lonza continued to be affected by customers’ efforts to optimise their overall cost base and net working capital. The company successfully implemented of a number of operational excellence programs which have increased the flexibility and throughput of most of its chemical manufacturing assets and will meet the new customer requirements. Lonza's biological manufacturing business continued to operate at high batch success rates, above the industry average and multiple new products and production campaigns had a positive impact on its mid- and large-scale asset utilisation.
Reuters
Wednesday, 21 July 2010
Tuesday, 20 July 2010
Angel posts H1 profit
Angel Biotechnology has reported a profit of £106,000 in the first six months of 2010. The company said it has secured business for the rest of the year and expects to post a profit for the full year.
The Herald
Eden to develop Itero biosimilar
Eden Biodesign will provide process development for Itero Biopharmaceutical’s biosimilar recombinant follicle stimulating hormone. The product has been licenced by Eden's parent company, Watson Pharmaceuticals.
San Francisco Business Journal
Thursday, 15 July 2010
Monday, 12 July 2010
Thursday, 8 July 2010
Jubilant to focus on life sciences
Jubilant Organosys is to spin off its agri-chem and performance polymer business units into a separate business Jubilant Industries and rename itself Jubilant Life Sciences.
Reuters
Tuesday, 6 July 2010
BASF merges Swiss fine chems units
BASF has merged its Evionnaz, Switzerland- based businesses BASF Orgamol Pharma Solutions and BASF Fine Chemicals Switzerland into a single organisation, BASF Pharma (Evionnaz). BASF said the merger reduces complexity at its site and simplifies processes.
In-Pharma Technologist
Thursday, 1 July 2010
Aesica acquires R5, plans more
Aesica has acquired R5, which develops and manufactures new medicines and clinical trial materials, for an undisclosed sum. Chief Executive, Robert Hardy, said the company is currently considering a number of additional takeover targets overseas as part of its expansion plans including a formulation manufacturer in the US and Europe.
North East Business
CPhI to be held in Frankfurt in 2011
The annual trade show will take place on 25-27 October 2011 at the Messe, Frankfurt.
PR Newswire
DCGI to inspect China plants
India's drug regulator, the Drug Controller General of India (DCGI), is planning to start inspecting manufacturers in China supplying intermediates and APIs to Indian manufacturers.
DWS Pillscribe
Wednesday, 23 June 2010
ICICI seeks buyer for RFCL
ICICI Ventures is looking to sell RFCL, which includes fine chemicals and in vitro diagnostics businesses. ICICI is believed to be looking to raise $87m.
Business Standard
Borregaard closes Italian plant
Borregaard Synthesis is closing its production plant in Ravenna, Italy, as a result of challenging market conditions which it does not see changing in the near future. 40 employees will be affected.
Borregaard
Tuesday, 22 June 2010
Ricerca gains DEA licence; ISO 9001 certification
Ricerca Biosciences has gained a US Drug Enforcement Agency (DEA) licence for its Concord, OH, facility which allows the company to produce controlled bulk APIs for phase I to II trials. Additionally, Ricerca's Lyon facility has obtained the ISO 9001:2008 certification. The company's Taipei facility received the ISO 9001:2008 certification in October 2009.
Outsourcing Pharma
Ricerca
Monday, 21 June 2010
UKTI seeks companies for UK pavilion at CPhI
UK Trade & Investment is seeking UK-based companies offering UK-origin products and services within the fine and speciality chemical industry, as well as relevant service providers to the pharmaceutical industry for the UK pavilion at CPhI in October.
For more information contact UKTI
Codexis and Merck receive Presidential award
Merck and Codexis have been awarded the Presidential Green Chemistry Challenge Award from the US Environmental Protection Agency for their development of a novel biocatalytic method for the synthesis of diabetes drug, sitagliptin. The award recognises new technologies that help prevent pollution by reducing or eliminating hazardous waste in industrial production. Additionally, the companies have published details of the process, which uses a customised enzyme to perform a key step in the synthesis, in the journal Science.
Codexis
Reuters
FDA plans new manufacturing rules
The US FDA is planning to new regulations to tighten up regulations for drugmakers that outsource manufacturing. The FDA said it may require drugmakers to conduct on-site audits of contract manufacturing facilities. Additionally, the agency is considering issuing warning letters to both the contact manufacturer and drugmaker if issues are found.
Wall Street Journal
Thursday, 17 June 2010
Jubilant invests in Gujarat
Jubilant Organosys is building two 10,000-tonne/year units at its special economic zone at Bharuch in Gujarat. One plant will produce niacinamide and the other 3-cyanopyridine.
Business Standard
SAFC invests in Scotland and Missouri facilities
Sigma-Aldrich's SAFC division is expanding its network of global 'Centers of Excellence' designed specifically to support the seamless upstream and downstream production of liquid cell culture reagents at its St. Louis, Missouri site and its Irvine, Scotland facility. The work is expected to finish in Q4 2010.
SAFC
Thursday, 10 June 2010
Lonza adds development services
Lonza has launched a new set of immunogenicity, stability and protein engineering services designed to improve the quality, safety, efficacy and manufacturability of antibodies, therapeutic proteins and vaccines. The Applied Protein Services platform complements the company's process development and manufacturing capabilities while advancing its efforts to incorporate Quality by Design (QbD) principles.
Lonza
Xcellerex building biomanufacturing facility
Xcellerex has started construction of its state-of-the-art cGMP biomanufacturing facility in Marlborough, MA. The facility will use Xcellerex's single use bioreactors and downstream unit operations to provide bridge biomanufacturing services for clients that are planning or building their own facilities using Xcellerex technology. The plant, which is due to be completed in September, will also support Xcellerex’s contract manufacturing operations.
Xcellerex
Tuesday, 8 June 2010
Albemare to build kilo-lab in Belgium
Albemarle fine chemistry services division is building a state of the art kilo lab in Louvain la Neuve, Belgium. The facility will contain the highest quality processes and safety features and have capabilities up to and including 50L glass lined vessels.
Albemarle
Ash Stevens to expand capacity
Ash Stevens will invest $20m to expand its API production capabilities in Riverview, MI, over the next five years. CEO Stephen Munk believes this will expand production by 50-80% and allow the company to hire another 50 workers. In the first phase Ash Stevens will add a 1000m
Crain's Detroit
Fine chems sales grow for Johnson Matthey
Sales at Johnson Matthey's Fine Chemicals Division rose 2% to £219m and operating profit rose 13% to £55.8m. The company expects to deliver steady growth in the divison, but said that H1 results this year would be impacted by the absence of the $12m one-off benefit in 2009/10 from the launch of the generic version of Adderall XR.
Johnson Matthey
Subscribe to:
Posts (Atom)
